-
Biotricity exchanges common, options, warrants for Series C preferred with 40 votes per share
14.14M common shares, 3.99M options, and 1.44M warrants exchanged for 1.96M Series C shares at a 10:1 ratio.
-
Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M
Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.
-
Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M
Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.
-
Biotricity Q3 FY25 revenue $3.6M (+21.7% YoY); net loss down 56.7% to $1.32M
Gross margin improved to 76.4% from 72.9% YoY; recurring tech fees 94% of revenue at 81.4% gross profit.
-
Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M
Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.
-
Biotricity receives Nasdaq delisting notice; trading suspended August 5, 2024
Nasdaq Hearings Panel determined to delist Biotricity's common stock; trading suspended at open Aug 5, 2024.
-
Biotricity receives Nasdaq bid price deficiency notice; 180-day cure period to Jan 22, 2025
Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq Listing Rule 5550(a)(2) deficiency.
-
Biotricity raises $500K in Series B Preferred placement; up to $1.5M additional
Issued 55 Series B Preferred shares at $9,090.91 each for gross proceeds of $500,000 on June 21, 2024.
-
Biotricity issues 8.95M common shares on conversion of Series A Preferred
Issued 8,952,172 common shares to investors upon conversion of 6,104 Series A Preferred shares plus accrued dividends and fees.
-
Biotricity faces Nasdaq delisting for missing annual meeting; closes $354k private placement
Nasdaq notified Biotricity on May 1, 2024 of non-compliance with annual meeting rule; additional delisting basis.
-
Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024
Panel granted listing continuation after hearing on April 9, 2024.
-
Biotricity raises $1M in private placement of Series B Preferred Stock, with option for additional $1M
Gross proceeds of $1M from sale of 110 Series B Convertible Preferred shares at $9,090.91 each.
-
Biotricity receives Nasdaq delisting determination for failure to meet MVLS requirement; intends to appeal
Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.
-
Biotricity raises $2M via Series B Convertible Preferred Stock at $3.50 conversion price, 8% dividend
Gross proceeds of $2,000,000 from sale of 220 Series B Preferred shares at $9,090.91 per share.
-
Biotricity Q1 FY2024 revenue up 46.9% to $3.0M; net loss improves 28% to $3.6M
Revenue $3.02M, up 46.9% YoY; recurring technology fees $2.8M, up 47% YoY.
-
Biotricity receives Nasdaq deficiency letter for MVLS below $35M minimum
On Aug 1, 2023, Biotricity received Nasdaq notice: MVLS < $35M for 30 consecutive business days.
-
Biotricity regains Nasdaq minimum bid price compliance
Received Nasdaq notice on July 18, 2023 confirming compliance with Rule 5550(a)(2).
-
Biotricity FY23 revenue up 26% to $9.64M, net loss narrows; 1:6 reverse split effective July 3
FY23 revenue grew 26% YoY to $9.64M; net loss decreased 35% to $19.5M.
-
Biotricity raises ~$1.22M net through convertible notes with 15% interest and warrants
Raised $1,218,930 net proceeds from $1,387,700 principal amount convertible notes at 15% interest, maturing one year from final closing.
-
Biotricity receives $2M from investor, plans 18-month promissory note at 10% interest
Received $2M in cash from an existing investor on January 23, 2023.
-
Biotricity receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq letter on Jan 20, 2023: closing bid price below $1.00 for 30 consecutive days.
-
Biotricity Q2 FY2023 revenue $2.4M, up 14% sequentially; net loss $4.9M
Revenue $2.4M, up 14% QoQ; gross profit $1.3M (54% margin).
-
Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M
FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.
-
Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M
Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.
-
Biotricity borrows $12M at LIBOR+10.5%, issues 57,536-share warrant to SWK Funding
Borrowed $12M from SWK Funding LLC at LIBOR plus 10.5% interest, maturing Dec 21, 2026.
-
Biotricity Q2 FY2022 revenue $1.81M (+143% YoY); net loss $11M includes $5.46M one-time costs
Revenue of $1.81 million, up 143% year-over-year; gross margin 62%.
-
Biotricity raises $15M in underwritten public offering, lists on Nasdaq Capital Market
Offered 5M shares at $3.00/share for ~$15M gross proceeds; H.C. Wainwright sole book-runner.
-
Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter
Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.
-
Biotricity issues preliminary Q1 FY2022 revenue guidance: up >45% QoQ
Revenue for Q1 ended June 30, 2021 expected to increase >45% sequentially and >280% YoY.